Wolfe Research has initiated coverage on Scholar Rock Holding Corp (SRRK) with an Outperform rating, marking the firm's first assessment of the biotechnology company. This rating reflects Wolfe's analysis of Scholar Rock's business, industry dynamics, and growth prospects.
Headquartered in Cambridge, Massachusetts, Scholar Rock focuses on advancing treatments for neuromuscular diseases, cardiometabolic disorders, and other serious conditions. The company has developed a proprietary platform for discovering monoclonal antibodies that target latent forms of growth factors. Its lead product candidate, apitegromab, is being developed as a potential first muscle-targeted therapy for spinal muscular atrophy (SMA).
As of November 17, 2025, Scholar Rock's shares are trading at $39.80, and the company boasts a market capitalization of $4.0 billion. While the firm reported a trailing twelve-month EPS of -2.91, upcoming earnings estimates suggest a continued focus on growth, with projections of -$0.84 EPS and $2.0 million in revenue for the quarter ending August 3, 2026.
Analyst ratings, including this latest one from Wolfe Research, provide insights into market perceptions but should be considered alongside company fundamentals and broader industry trends. As of November 1, 2025, the consensus among analysts is a Buy, with 7 Strong Buy, 11 Buy, and 1 Hold ratings. Analyst opinions can shift as new data emerges, highlighting the importance of a comprehensive approach to investment decisions.